Interview with Professor He Huang: Exploring New Cellular Immunotherapies

Interview with Professor He Huang: Exploring New Cellular Immunotherapies

2024.05.12
From April 14 to 17, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, marking the 50th anniversary of EBMT. This event gathered leaders in hematopoietic stem cell transplantation and over 6,000 hematology experts worldwide to reflect on the extraordinary achievements in the field over the past half-century and to explore future patient management strategies. At the conference, Professor He Huang from the First Affiliated Hospital of Zhejiang University College of Medicine shared significant advancements in novel cellular immunotherapies, capturing the attention of many. This publication has invited Professor Huang for an in-depth interview to discuss the innovations in the field of cellular immunotherapy.
Professor Apolo Discusses the Addition of Adjuvant Immunotherapy for Urothelial Carcinoma in the AMBASSADOR Study | 2024 ASCO-GU Conference

Professor Apolo Discusses the Addition of Adjuvant Immunotherapy for Urothelial Carcinoma in the AMBASSADOR Study | 2024 ASCO-GU Conference

2024.05.11
Based on the CheckMate -274 study, nivolumab became the world's first approved immunotherapy for adjuvant treatment of urothelial carcinoma, while the IMvigor 010 did not achieve positive DFS results, leading to the subsequent focus on ctDNA (MRD) positive patients in the IMvigor 011 study. At the recent 2024 ASCO-GU conference, the results of the pembrolizumab adjuvant therapy AMBASSADOR study were reported. This study uniquely set both DFS and OS as dual endpoints, achieving positive results for DFS, though the control group's receipt of immunotherapy may impact the OS endpoint. "Oncology Frontier" interviewed the study's presenter, Professor Andrea B. Apolo from the National Cancer Institute (NCI), at the conference.
Professor Chuanliang Cui Interprets the Key Updates of the Urothelial Carcinoma Guidelines | 2024 CSCO Guidelines Conference

Professor Chuanliang Cui Interprets the Key Updates of the Urothelial Carcinoma Guidelines | 2024 CSCO Guidelines Conference

2024.05.11
Urothelial carcinoma is one of the most common malignant tumors in the urinary system, and its treatment strategies have undergone many changes in recent years. Although traditional chemotherapy has played a significant role in the treatment of urothelial carcinoma, the development of new drugs such as immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) has brought about new breakthroughs in treatment. At the recent 2024 CSCO Guidelines Conference, "Oncology Frontier" was fortunate to invite Professor Cui Chuanliang from Peking University Cancer Hospital to provide an in-depth interpretation of the key updates to the 2024 CSCO urothelial carcinoma guidelines.
Impact of β-Lactam Antibiotics on Gut Microbiota –  – Interview with Prof. Etienne RUPPÉ

Impact of β-Lactam Antibiotics on Gut Microbiota –  – Interview with Prof. Etienne RUPPÉ

2024.05.11
Prof. Etienne Ruppé, a professor of bacteriology at the Université Paris Cité and researcher at the IAME unit, is conducting a study on the impact of β-lactam antibiotics on the gut microbiota. His research primarily focuses on ceftriaxone, piperacillin-tazobactam, and ceftazidime-avibactam, uncovering significant findings regarding the differential impacts and lasting effects of these antibiotics on gut microbial communities. We interviewed Prof. Ruppé to discuss his research findings and their potential implications for antibiotic therapy and microbial health.
Advances in Endocarditis Diagnosis – An In-Depth Interview with Dr. Maria Nazarena Pizzi

Advances in Endocarditis Diagnosis – An In-Depth Interview with Dr. Maria Nazarena Pizzi

2024.05.11
In the dynamic field of infectious diseases, guidelines must adapt to reflect ongoing research and technological advancements to ensure the highest standards of patient care. The 2023 European Society of Cardiology (ESC) Guidelines for the diagnosis of endocarditis mark a significant advancement in how clinicians approach this complex disease. To gain deeper insights into these important changes, Infectious Disease Frontier interviewed Dr. Maria Nazarena Pizzi, a leading cardiologist and expert in cardiac imaging at Vall d'Hebron University Hospital in Barcelona, Spain. Dr. Pizzi, with her extensive involvement in the development of these guidelines, shares her valuable perspective on their implications for clinical practice
EBMT Interview | The Latest Advances and Challenges in Bispecific Antibody Treatment for Lymphoma

EBMT Interview | The Latest Advances and Challenges in Bispecific Antibody Treatment for Lymphoma

2024.05.10
Monoclonal antibody-based targeted therapy has significantly improved treatment options for cancer patients. In recent years, advancements in protein engineering have led to the development of bispecific antibodies (BsAbs), marking a paradigm shift in antibody construction usage. BsAbs, recognized for their higher therapeutic response, resistance barrier, and fewer adverse reactions, have caught significant attention in the academic world. The next wave of "bispecific or multispecific antibodies" is also on the horizon. At the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Professor Maria Gomes Da Silva from the Portuguese Oncology Institute delivered an insightful report on the latest advances in BsAb treatments for lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Da Silva to share the latest developments and challenges in this field with our readers.
EBMT Spotlight Interview | Professor Li Chunfu: Improved TCRαβ-T Cell Depleted Hematopoietic Stem Cell Transplantation (TDH) for Treating Severe Thalassemia

EBMT Spotlight Interview | Professor Li Chunfu: Improved TCRαβ-T Cell Depleted Hematopoietic Stem Cell Transplantation (TDH) for Treating Severe Thalassemia

2024.05.10
Hematopoietic stem cell transplantation is a common and effective treatment in the field of hematology. As techniques have matured, stem cell transplantation not only serves as a treatment for malignant blood diseases such as leukemia but also offers a new solution for curing thalassemia. The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting took place in Glasgow, UK, from April 14th to 17th, 2024. The conference highlighted the latest advancements in stem cell transplantation and cellular therapies, pushing hematologic patients towards better clinical outcomes. At this meeting, Professor Li Chunfu from the Gaobo Medical (Hematology) Guangdong Research Center and Southern Chunfu (Children’s) Hematology Institute delivered an excellent oral presentation on the modified TCRαβ-T cell depleted hematopoietic stem cell transplantation (TDH) for treating severe thalassemia. "Oncology Frontier - Hematology Frontier" invited Professor Li to share his insights and experiences regarding transplantation treatments for thalassemia with our readers.
EBMT Interview Spotlight | Latest Advances and Challenges in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

EBMT Interview Spotlight | Latest Advances and Challenges in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

2024.05.09
Acute Lymphoblastic Leukemia (ALL) is a malignant neoplastic disease that originates from B-cell or T-cell lymphocytes and proliferates abnormally in the bone marrow. In recent years, immunotherapy has made significant strides in the field of ALL, including breakthroughs in treatments such as Chimeric Antigen Receptor T-cell (CAR-T) therapy, bispecific antibodies, and antibody-drug conjugates (ADC). The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. At the conference, Professor Peter Bader from the Department of Stem Cell Transplantation, Immunology, and Intensive Care Medicine at the University Hospital Frankfurt, Germany, delivered a special report on the current application of CAR-T therapy in ALL patients. Hematology Frontier invited Professor Bader to share the latest progress and challenges in CAR-T therapy in the field of ALL with a wide audience.